Global and Local Epidemiology of Community-Acquired Pneumonia: The Experience of the CAPNETZ Network

Tobias Welte; Thomas Köhnlein

doi:10.1055/s-0029-1202941

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2009; 30(2): 127-135
DOI: 10.1055/s-0029-1202941

Global and Local Epidemiology of Community-Acquired Pneumonia: The Experience of the CAPNETZ Network

Tobias Welte¹ , Thomas Köhnlein¹

¹Department of Pulmonary Medicine, Medizinische Hochschule Hannover, Hannover, Germany

Abstract

ABSTRACT

Community-acquired pneumonia (CAP) is a major cause of morbidity and mortality worldwide. Young children and the elderly are disproportionately affected by CAP. Lower respiratory tract infections (LRTIs), including CAP, were ranked third in a list of the 30 leading causes of death worldwide in 1990. Mortality rates are low (< 2%) in CAP patients treated as outpatients, but are higher (5 to 20%) among patients hospitalized for CAP, and are highest (up to 50%) in patients admitted to the intensive care unit. Several risk factors are known to be associated with increases in mortality, the most important of which are age > 65 years, male gender, and comorbidities such as chronic heart failure, advanced chronic obstructive pulmonary disease, neurological diseases, and liver cirrhosis. Patients living in nursing homes may have a special risk for multiresistant bacterial infection. The incidence of CAP varies worldwide by country, age, and gender. Further, data about epidemiology, etiology, morbidity, mortality, and economical burden of diseases differ between countries. In this review, we present recent data regarding the incidence, etiology, and rate of antibiotic resistance among CAP patients from the German Network for Community Acquired Pneumonia (CAPNETZ) registry and review data from several European countries.

KEYWORDS

Community-acquired pneumonia - Europe - incidence - lower respiratory tract infections

Full Text

References

REFERENCES

1 Murray C JL, Lopez A D. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997; 349 1269-1276
2 Bundesgeschäftsstelle für Qualitätssicherung . Qualitätsreport BQS 2007 Hrg. Düsseldorf. 2008; 28-34
3 Welte T, Suttorp N, Marre R. CAPNETZ–community-acquired pneumonia competence network. Infection. 2004; 32 234-238
4 Trotter C L, Stuart J M, George R, Miller E. Increasing hospital admissions for pneumonia, England. Emerg Infect Dis. 2008; 14 727-733
5 European Respiratory Society/European Lung Foundation .Pneumonia. In: European Respiratory Society/European Lung Foundation. European Lung White Book. Sheffield, UK; 2003: 55-65
6 Schnoor M, Hedicke J, Dalhoff K, Raspe H, Schafer T. CAPNETZ study group: approaches to estimate the population-based incidence of community acquired pneumonia. J Infect. 2007; 55 233-239
7 Mandell L A. Spectrum of microbial etiology of community- acquired pneumonia in hospitalized patients: implications for selection of the population for enrollment in clinical trials. Clin Infect Dis. 2008; 47 S189-S192
8 Marston B J, Plouffe J F, File T M et al.. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med. 1997; 157 1709-1718
9 Niederman M S, McCombs J S, Unger A N, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther. 1998; 20 820-837
10 Monge V, San-Martin M, Gonzalez A. The burden of community-acquired pneumonia in Spain. Eur J Public Health. 2001; 11 362-364
11 United Nations Population Division .World population prospects: the 2006 revision population database. Available at http://esa.un.org/unpp/p2k0data.asp Accessed October 25, 2008
12 Bartolome M, Almirall J, Morera J Maresme Community-Acquired Pneumonia Study Group (GEMPAC) et al. A population-based study of the costs of care for community-acquired pneumonia. Eur Respir J. 2004; 23 610-616
13 Bauer T T, Welte T, Ernen C et al.. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest. 2005; 128 2238-2246
14 Restrepo M I, Mortensen E M, Valez J A et al.. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest. 2008; 133 610-617
15 Welte T, Marre R, Suttorp N. Kompetenznetzwerk “Ambulant Erworbene Pneumonie” (CAPNETZ) . What is new in the treatment of community-acquired pneumonia? [in German]. Med Klin (Munich). 2006; 101 313-320
16 Koivula I, Stén M, Mäkelä P H. Prognosis after community-acquired pneumonia in the elderly: a population-based 12-year follow-up study. Arch Intern Med. 1999; 159 1550-1555
17 Yende S, D'Angelo G, Kellum J A GenIMS Investigators et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med. 2008; 177 1242-1247
18 El Solh A, Pineda L, Bouquin P, Mankowski C. Determinants of short and long term functional recovery after hospitalization for community-acquired pneumonia in the elderly: role of inflammatory markers. BMC Geriatr. 2006; 6 12
19 Garbino J, Sommer R, Gerber A et al.. Prospective epidemiologic survey of patients with community-acquired pneumonia requiring hospitalization in Switzerland. Int J Infect Dis. 2002; 6 288-293
20 Giorgi Rossi P, Agabiti N, Faustini A et al.. The burden of hospitalised pneumonia in Lazio, Italy, 1997–1999. Int J Tuberc Lung Dis. 2004; 8 528-536
21 Froes F. Pneumonia in the adult population in continental Portugal: incidence and mortality in hospitalized patients from 1998 to 2000 [in Spanish]. Rev Port Pneumol. 2003; 9 187-194
22 Falcó V, Almirante B, Jordano Q et al.. Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains?. J Antimicrob Chemother. 2004; 54 481-488
23 Aspa J, Rajas O, Rodríguez de Castro F Pneumococcal Pneumonia in Spain Study Group et al.. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis. 2004; 38 787-798
24 Viegi G, Pistelli R, Cazzola M et al.. Epidemiological survey on incidence and treatment of community acquired pneumonia in Italy. Respir Med. 2006; 100 46-55
25 Foley S C, Kelly E M, O'Neill S J. Audit of the management of patients admitted with community acquired pneumonia. Ir Med J. 2006; 99 138-140
26 Menéndez R, Torres A, Zalacain R Neumofail Group et al.. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax. 2004; 59 960-965
27 Ochoa-Gondar O, Vila-Córcoles A, de Diego C EVAN-65 Study Group et al.. The burden of community-acquired pneumonia in the elderly: the Spanish EVAN-65 study. BMC Public Health. 2008; 8 222
28 Braun J J, de Graaff C S, de Goey J, Zwinderman A H, Petit P LC. Community-acquired pneumonia: pathogens and course in patients admitted to a general hospital [in Dutch]. Ned Tijdschr Geneeskd. 2004; 148 836-840
29 Paganin F, Lilienthal F, Bourdin A et al.. Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor. Eur Respir J. 2004; 24 779-785
30 Rello J, Bodi M, Mariscal D et al.. Microbiological testing and outcome of patients with severe community-acquired pneumonia. Chest. 2003; 123 174-180
31 Vallès X, Marcos A, Pinart M et al.. Hospitalized community-acquired pneumonia due to Streptococcus pneumoniae: has resistance to antibiotics decreased?. Chest. 2006; 130 800-806
32 Rosón B, Carratalà J, Fernández-Sabé N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med. 2004; 164 502-508
33 Bonnard P, Lescure F X, Douadi Y et al.. Community-acquired bacteraemic pneumococcal pneumonia in adults: effect of diminished penicillin susceptibility on clinical outcome. J Infect. 2005; 51 69-76
34 Melegaro A, Edmunds W J, Pebody R, Miller E, George R. The current burden of pneumococcal disease in England and Wales. J Infect. 2006; 52 37-48
35 Kothe H, Bauer T, Marre R, Suttorp N, Welte T, Dalhoff K. Competence Network for Community-Acquired Pneumonia Study Group . Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J. 2008; 32 139-146
36 Kollef M H, Shorr A, Tabak Y P et al.. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest. 2005; 128 3854-3862
37 Echols R M, Tillotson G S, Song J X, Tosiello R L. Clinical trial design for mild-to-moderate community-acquired pneumonia: an industry perspective. Clin Infect Dis. 2008; 47(Suppl 3) S166-S175
38 Nielsen S V, Poullsen K, Jørgensen L M, Rasmussen E, Sanders S, Henrichsen J. Incidence and diagnosis of cases of pneumonia caused by pneumococci that required hospitalization [in Danish]. Ugeskr Laeger. 1992; 154 412-415
39 Jokinen C, Heiskanen L, Juvonen H et al.. Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in eastern Finland. Clin Infect Dis. 2001; 32 1141-1154
40 Lim W S, Macfarlane J T, Boswell T CJ et al.. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax. 2001; 56 296-301
41 Welte T. Treatment of hospitalized patients with community-acquired pneumonia: reply [letter]. Clin Infect Dis. 2006; 43 110
42 Beović B, Bonac B, Kese D et al.. Aetiology and clinical presentation of mild community-acquired bacterial pneumonia. Eur J Clin Microbiol Infect Dis. 2003; 22 584-591
43 Fernandez Alvarez R, Suarez Toste I, Rubinos Cuadrado G et al.. Community-acquired pneumonia: aetiologic changes in a limited geographic area. An 11-year prospective study. Eur J Clin Microbiol Infect Dis. 2007; 26 495-499
44 Guglielmo L, Leone R. Veneto Pneumonia Research Group . Aetiology and therapy of community-acquired pneumonia: a hospital study in northern Italy. Eur J Clin Pharmacol. 1997; 51 437-443
45 Ostergaard L, Andersen P L. Etiology of community-acquired pneumonia: evaluation by transtracheal aspiration, blood culture, or serology. Chest. 1993; 104 1400-1407
46 Laurichesse H, Sotto A, Bonnet E Infectio-Sud Study Group et al.. Pre- and in-hospital management of community-acquired pneumonia in Southern France, 1998–99. Eur J Clin Microbiol Infect Dis. 2001; 20 770-778
47 Wellinghausen N, Straube E, Freidank H, von Baum H, Marre R, Essig A. Low prevalence of Chlamydia pneumoniae in adults with community-acquired pneumonia. Int J Med Microbiol. 2006; 296 485-491
48 von Baum H, Ewig S, Marre R Competence Network for Community Acquired Pneumonia Study Group et al. Community-acquired Legionella pneumonia: new insights from the German competence network for community acquired pneumonia. Clin Infect Dis. 2008; 46 1356-1364
49 De Roux A, Marcos M A, Garcia E et al.. Viral community-acquired pneumonia in nonimmunocompromised adults. Chest. 2004; 125 1343-1351
50 Apisarnthanarak A, Mundy L M. Etiology of community-acquired pneumonia. Clin Chest Med. 2005; 26 47-55
51 Vanderkooi O G, Low D E, Green K, Powis J E, McGeer A. for the Toronto Invasive Bacterial Disease Network . Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis. 2005; 40 1288-1297
52 Yu V L, Chiou C CC, Feldman C International Pneumococcal Study Group et al.. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis. 2003; 37 230-237
53 Daneman N, McGeer A, Green K, Low D E. Toronto Invasive Bacterial Diseases Network . Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis. 2006; 43 432-438
54 Whitney C G, Farley M M, Hadler J et al.. Active bacterial core surveillance of the emerging infections program network: invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N Engl J Med. 2003; 348 1737-1746
55 Stephens D S, Zughaier S M, Whitney C G Georgia Emerging Infections Program et al.. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet. 2005; 365 855-863
56 Low D E. Quinolone resistance among pneumococci: therapeutic and diagnostic implications. Clin Infect Dis. 2004; 38(Suppl 4) S357-S362
57 Woodhead M, Blasi F, Ewig S et al.. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005; 26 1138-1180

Tobias WelteM.D.

Department of Pulmonary Medicine, Medizinische Hochschule Hannover

Carl Neuberg Strasse 1, D-30625 Hannover, Germany

Email: welte.tobias@mh-hannover.de